GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OHEL:NANOFH) » Definitions » Gross Margin %

Nanoform Finland (OHEL:NANOFH) Gross Margin % : 73.75% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Nanoform Finland's Gross Profit for the three months ended in Dec. 2023 was €0.30 Mil. Nanoform Finland's Revenue for the three months ended in Dec. 2023 was €0.40 Mil. Therefore, Nanoform Finland's Gross Margin % for the quarter that ended in Dec. 2023 was 73.75%.


The historical rank and industry rank for Nanoform Finland's Gross Margin % or its related term are showing as below:

OHEL:NANOFH' s Gross Margin % Range Over the Past 10 Years
Min: -1130.61   Med: 66.91   Max: 91.66
Current: 66.9


During the past 8 years, the highest Gross Margin % of Nanoform Finland was 91.66%. The lowest was -1130.61%. And the median was 66.91%.

OHEL:NANOFH's Gross Margin % is ranked better than
56.67% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs OHEL:NANOFH: 66.90

Nanoform Finland had a gross margin of 73.75% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Nanoform Finland was 0.00% per year.


Nanoform Finland Gross Margin % Historical Data

The historical data trend for Nanoform Finland's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland Gross Margin % Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial -1,130.61 68.41 91.66 90.25 66.91

Nanoform Finland Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.45 78.36 63.85 53.04 73.75

Competitive Comparison of Nanoform Finland's Gross Margin %

For the Biotechnology subindustry, Nanoform Finland's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's Gross Margin % falls into.



Nanoform Finland Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Nanoform Finland's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1.7 / 2.566
=(Revenue - Cost of Goods Sold) / Revenue
=(2.566 - 0.849) / 2.566
=66.91 %

Nanoform Finland's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.3 / 0.4
=(Revenue - Cost of Goods Sold) / Revenue
=(0.4 - 0.105) / 0.4
=73.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nanoform Finland  (OHEL:NANOFH) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nanoform Finland had a gross margin of 73.75% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Nanoform Finland Gross Margin % Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland (OHEL:NANOFH) Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OHEL:NANOFH) Headlines

No Headlines